// App-Quantinova.ai

TPS5087 : ATLAS: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy.

Researchers

Presenter

  • Howard M. Sandler

Principal Investigators

  • Michael R. McKenzie

  • Bertrand F. Tombal

  • Edwina Baskin-Bey

  • Stephen J. Freedland

  • Mack Roach

  • Anders Widmark

  • Alberto Bossi

  • Adam Dicker

  • Thomas Wiegel

  • Neal D. Shore

  • Matthew Raymond Smith

  • Margaret K. Yu

  • Thian Kheoh

  • Shibu Thomas

  • David P. Dearnaley

Medical Centers

  • Cedars-Sinai Medical Center, Los Angeles, CA

  • British Columbia Cancer Agency, Vancouver, BC, Canada

  • Cliniques Universitaires Saint-Luc, UCL, Brussels, MN, Belgium

  • Janssen Research & Development, Los Angeles, CA

  • Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

  • Umea University, Umea, Sweden

  • Institut Gustave-Roussy, Villejuif, France

  • The Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA

  • University of Ulm, Ulm, Germany

  • Carolina Urologic Research Center, Myrtle Beach, SC

  • Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA

  • Janssen Research & Development, San Diego, CA

  • Janssen Pharmaceuticals, Spring House, PA

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

Locations

  • Canada

  • Germany

  • United Kingdom

  • United States

  • France

  • Belgium

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Bicalutamide

  • ARN-509

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT02531516

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved